Endothelial Dysfunction and Its Critical Role in COVID-19-associated Coagulopathy: Defibrotide As an Endothelium-protective, Targeted Therapy
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Palomo M, Moreno-Castano A, Salas M, Escribano-Serrat S, Rovira M, Guillen-Olmos E Front Med (Lausanne). 2023; 10:1285898.
PMID: 38034541 PMC: 10682735. DOI: 10.3389/fmed.2023.1285898.
Defibrotide Therapy for SARS-CoV-2 ARDS.
Frame D, Scappaticci G, Braun T, Maliarik M, Sisson T, Pipe S Chest. 2022; 162(2):346-355.
PMID: 35413279 PMC: 8993696. DOI: 10.1016/j.chest.2022.03.046.
References
1.
Richardson P, Carreras E, Iacobelli M, Nejadnik B
. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018; 2(12):1495-1509.
PMC: 6020812.
DOI: 10.1182/bloodadvances.2017008375.
View
2.
Goshua G, Pine A, Meizlish M, Chang C, Zhang H, Bahel P
. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020; 7(8):e575-e582.
PMC: 7326446.
DOI: 10.1016/S2352-3026(20)30216-7.
View
3.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis T, Politou M
. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7):834-847.
PMC: 7262337.
DOI: 10.1002/ajh.25829.
View
4.
Levi M, Iba T
. COVID-19 coagulopathy: is it disseminated intravascular coagulation?. Intern Emerg Med. 2020; 16(2):309-312.
PMC: 7758412.
DOI: 10.1007/s11739-020-02601-y.
View
5.
Buijsers B, Yanginlar C, Maciej-Hulme M, de Mast Q, van der Vlag J
. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine. 2020; 59:102969.
PMC: 7445140.
DOI: 10.1016/j.ebiom.2020.102969.
View